ATRA - Atara Biotherapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5737.89M
Enterprise Value 3616.12M
Trailing P/E N/A
Forward P/E 1-3.07
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.60
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.39

Trading Information

Stock Price History

Beta (3Y Monthly) 3.07
52-Week Change 3-55.33%
S&P500 52-Week Change 37.29%
52 Week High 343.95
52 Week Low 315.31
50-Day Moving Average 321.01
200-Day Moving Average 331.65

Share Statistics

Avg Vol (3 month) 3768.46k
Avg Vol (10 day) 3814.8k
Shares Outstanding 530.73M
Float 32.69M
% Held by Insiders 14.86%
% Held by Institutions 1111.63%
Shares Short (Jun 28, 2019) 47.95M
Short Ratio (Jun 28, 2019) 410.54
Short % of Float (Jun 28, 2019) 424.50%
Short % of Shares Outstanding (Jun 28, 2019) 417.15%
Shares Short (prior month May 31, 2019) 47.98M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-41.13%
Return on Equity (ttm)-70.67%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -257.44M
Net Income Avi to Common (ttm)-255.51M
Diluted EPS (ttm)-5.62
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)237.54M
Total Cash Per Share (mrq)5.13
Total Debt (mrq)15.72M
Total Debt/Equity (mrq)5.54
Current Ratio (mrq)9.96
Book Value Per Share (mrq)6.13

Cash Flow Statement

Operating Cash Flow (ttm)-215.15M
Levered Free Cash Flow (ttm)-140.77M